OpenEvidence Doubles to $12 Billion, Fueling AI Gold Rush in Healthcare and Raising Big Conservative Questions
Doctors or Algorithms? $250M Round Supercharges Medical AI-But Who Controls the Future?
‘If a doctor tried to stay current by reading only the new evidence in the top 10 medical journals and only the most recent changes to their specialty guidelines, it would take nine hours of their day, each day.’-OpenEvidence CEO Daniel Nadler, sounding the alarm on information overload.
The AI takeover isn’t patiently waiting at the horizon-it’s here, and Silicon Valley’s latest darling, OpenEvidence, is making waves that could break the healthcare system as we know it. In barely three months, OpenEvidence has doubled its valuation to an eye-watering $12 billion thanks to a $250 million cash infusion from heavyweights like Thrive Capital, DST Global, Sequoia, Nvidia, and even the Mayo Clinic.
This isn’t just another startup with dreams of replacing doctors with robots. In December alone, OpenEvidence’s so-called ‘free, ad-supported’ platform was used in 18 million clinical consultations-up six-fold from just a year prior, as verified U.S. clinicians flocked to its AI engine searching for instant answers. It sounds innovative, but behind the glossy funding headlines, uncomfortable questions about medical data, power, and America’s healthcare future are stacking up fast.
“Every conservative should be asking: When it comes to your body and your loved ones, do you want doctors deciding with real-world experience, or Silicon Valley coders tweaking the algorithm from the comfort of San Francisco?”
Let’s break down how OpenEvidence got here-and why the winners in today’s ‘AI-for-doctors’ gold rush might not be ordinary Americans, but the same private equity, Big Tech, and institutional behemoths that profit while our out-of-pocket costs keep rising.
Inside OpenEvidence’s Meteoric Rise: The AI Stampede Reshaping Healthcare
From unicorn to mega-decaporn in a year-OpenEvidence is riding a funding rocket few can match. When it scored $75M at a $1 billion valuation in February 2025, some called it the most promising startup for doctors since the stethoscope. Fast-forward to October: a $200 million round at $6 billion. Now a $250 million windfall at $12 billion.
Investors are scrambling over themselves for a piece of the platform, despite fierce competition from OpenAI, Anthropic, and Google Health. What sets OpenEvidence apart, its founders claim, is a strict focus on training exclusively on medical literature-not generic web nonsense-and official partnerships with giants like The New England Journal of Medicine, the American Medical Association, and the National Comprehensive Cancer Network.
With its ‘agentic research assistant’ and medical scribing tools rolled out, OpenEvidence promises to slash paperwork, streamline diagnoses, and keep overwhelmed clinicians at the cutting edge. But as the AI revolution accelerates, some industry experts suspect a lot more is at stake.
“This is a business model well beyond selling ads to doctors’ eyeballs. Investor optimism is rooted in OpenEvidence’s pursuit of what we call ‘medical superintelligence.'”-PitchBook analyst Brian Wright
It’s not just hype-revenue is surging too. OpenEvidence has surpassed $100 million in annual sales, and with elite investors from Blackstone to Nvidia piling in, it’s clear big money sees huge profit in clinical decision AI. The company plans to double down on research, development, and compute power-a move sure to accelerate the pace of medical automation.
Meanwhile, the lawsuit drama heats up: OpenEvidence has gone to court against a rival, Pathway Medical, who they claim tried to ‘compromise’ their platform and steal trade secrets through stolen credentials and ‘malicious inputs.’ The AI arms race isn’t just about funding-it’s already getting cutthroat, with accusations of intellectual property theft hinting at high-stakes battles to come.
Winners, Losers, and the Real Stakes for American Patients and Physicians
As AI explodes in medicine, who will really benefit-the American people or the coastal elite technocrats? While Wall Street, venture capitalists, and coastal investors are licking their chops, doctors across the heartland are already warning that a Silicon Valley–led healthcare revolution could mean more bureaucracy, more impersonal care, and less local control.
It’s easy for OpenEvidence boosters to pitch their platform as a lifesaver, but the reality on the ground is complicated. Rural clinics are still struggling for reliable high-speed internet, let alone robust AI support. Many conservative practitioners, already fed up with federal mandates and medical red tape, see another top-down tech solution not as help, but as a potential threat to their autonomy and professional judgment.
Critically, OpenEvidence’s power comes from its ‘free’ access to millions of real-world U.S. clinicians-feeding detailed clinical queries into the system, fueling its data-hungry algorithms. Once AI becomes the default, what safeguards exist for doctor-patient privacy? Who is making sure conservative values-parental rights, patient choice, religious conscience-are respected by developers hundreds or thousands of miles away?
“Who owns your diagnosis-the doctor you trust, or the Big Tech engine parsing your data for the next investor pitch?”
And let’s not forget the elephant in the room. Under President Trump, America is finally putting American innovation-and American patients-first. But when tech is moving at breakneck speed, more oversight is essential. The stakes couldn’t be higher, with OpenEvidence boasting partnerships with the top medical journals and societies-meaning their algorithms will anchor much of the mainstream ‘medical consensus’ going forward. With the Biden-era regulatory maze thankfully left behind, conservatives must advocate to keep health freedom and clinical common sense at the center of these brave new platforms.
As we look to 2026’s midterm races, the question will echo on campaign trails from Iowa to Idaho: Is Main Street medicine about to get hijacked by Silicon Valley, or can we chart a conservative, patient-first course through the AI revolution? One thing is certain-while OpenEvidence’s valuation climbs, so do the stakes for healthcare sovereignty, privacy, and the future of American healthcare decision-making.
